Evidence map›Paper›PMID 42638638›Full record

ArticleFrontiers in tuberculosis2024

Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report.

Rebecca A Clark, Carly Young, Shaun Palmer, Erick Auma, Shelly Malhotra, Rupali Limaye, Birgitte Giersing, Lewis Schrager, Gerald Voss, Edine Tiemersma and 7 more

Abstract read
In one paragraph

Article in Frontiers in tuberculosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rebecca A Clark *TB Modelling Group and TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Carly Young *South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Shaun Palmer *Stichting International AIDS Vaccine Initiative, Amsterdam, Netherlands.
Erick Auma *Stop TB Partnership Working Group on New TB Vaccines, New York, NY, United States.
Shelly MalhotraInternational AIDS Vaccine Initiative, New York, NY, United States.
Rupali LimayeInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Birgitte GiersingInitiative for Vaccine Research, World Health Organization, Geneva, Switzerland.
Lewis SchragerInternational AIDS Vaccine Initiative, New York, NY, United States.
Gerald VossTuBerculosis Vaccine Initiative (TBVI), Lelystad, Netherlands.
Edine TiemersmaKNCV Tuberculosis Foundation, Amsterdam, Netherlands.
Mike FrickTreatment Action Group, New York, NY, United States.
Ijeoma EdokaHealth Economics and Epidemiology Research Office (HE2RO), Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Alemnew F DagnewBill & Melinda Gates Medical Research Institute, Cambridge, MA, United States.
Thokozile NkhomaFacilitators of Community Transformation (FACT) Malawi, Lilongwe, Malawi.
TB Vaccine Country Data Needs Group
Puck T PelzerStichting International AIDS Vaccine Initiative, Amsterdam, Netherlands.
Richard G WhiteTB Modelling Group and TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Funding

Defining drivers of TB transmission in the era of universal ART, and implications for finding the walking wellR01AI147321 · NIAID · LONDON SCH/HYGIENE & TROPICAL MEDICINE · PI GRANT, ALISON · 2019 to 2024
$2.3M
Bill & Melinda Gates Foundation INV-035506NIAID NIH HHS R01 AI147321Wellcome Trust
6 · The paper itself

Abstract

High tuberculosis (TB) burden countries (HBCs) need to prepare for TB vaccine implementation alongside licensure, to ensure rapid rollout. WHO policy/implementation frameworks have been created to support this effort. Using WHO frameworks, we convened a workshop to ask HBC experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction. For required data, we asked HBC and global experts which data were already available, data collection planned, or gaps. HBC experts expressed high demand for epidemiological, impact, feasibility and acceptability data, reported variable availability of existing epidemiological data, and low availability for impact, feasibility, and acceptability data. Global experts reported additional knowledge of existing data on impact, upcoming collection of infection prevalence, acceptability and feasibility data, and potential epidemiological data collection on adolescents, adults, people living with HIV, and underweight individuals. HBC and global experts made key recommendations for: a coordinated data collation, collection, analysis and sharing system; updating existing HBC health and economic impact estimates and extending impact analyses to other HBCs; demand/market forecasting; resource gap mapping; aligning delivery strategies; addressing manufacturing, procurement, delivery, and regulatory barriers; sharing potential vaccine licensure timing; incorporating TB vaccine introduction strategies into NSPs, immunization programs, and health services; collecting vaccine hesitancy, mistrust, and misinformation data; collecting adolescent/adult vaccine demand generation data, and identifying funding. Experts recommended expanding this analysis to other areas of the WHO frameworks, including more HBC stakeholders, and repeating this analysis after country and community advocacy and socialization around different vaccine candidates.

Indexed as

acceptabilityadolescents and adultsepidemiologyfeasibilityimpact modelingtuberculosisvaccines

Identifiers

PMID42638638
PMCPMC13494980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.